The FDA will soon decide on Merck's COVID-19 pill. Here are what experts say are the pros and cons

A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.

Related Keywords

Alabama ,United States ,United Kingdom ,Todd Sherer ,Brandon Malone ,Daria Hazuda ,Mark Denison ,Elizabeth Campbell ,Rustem Ismagilov ,Davidson Goldin ,Peter Hotez ,Eric Rubin ,Wendy Holman ,Ridgeback Biotherapeutics ,Emory Office Of Technology ,Vanderbilt University Medical Center ,Rockefeller University Lethal ,National Institute Of Allergy ,Drug Administration ,Advisory Committee ,Cnn ,Antimicrobial Drugs Advisory Committee ,Pfizer ,California Institute Of Technology ,Emory University In Atlanta ,Baylor College Of Medicine ,Defense Threat Reduction Agency ,George Painter ,Emory University ,Vanderbilt University Medical ,Middle East Respiratory Syndrome ,Public Health ,New England Journal ,Baylor College ,Rockefeller University ,Nature Structural ,Molecular Biology ,Cal Tech ,California Institute ,Drugs Advisory Committee ,National Institute ,Infectious Diseases ,Emory In January ,Drug Innovation Ventures ,Jbnd ,Merck ,Coronavirus ,Covid 19 ,Hill ,Fda ,Review ,Experts ,Medication ,Research ,